Efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus undergoing coronary artery bypass graft surgery: A non‐inferiority randomized trial. Issue 1 (16th November 2022)

• Record Type: Journal Article
• Authors: Kuchay, Mohammad Shafi; Mathew, Anu; Mishra, Mitali; Surendran, Parvathi; Kaur, Parjeet; Wasir, Jasjeet Singh; Gill, Harmandeep Kaur; Jain, Rujul; Gagneja, Sakshi; Kohli, Chhavi; Kumari, Poonam; Singh, Manish Kumar; Mishra, Sunil Kumar
• Is Part Of: Diabetic medicine. Volume 40:Issue 1(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-11-16
• Subjects: continuous glucose monitoring system -- degludec U100 -- glargine U300 -- hospital care -- hypoglycemia -- inpatient management; Diabetes -- Periodicals; 616.462
• DOI: 10.1111/dme.15002
• Languages: English
• ISSNs: 0742-3071

Abstract

Abstract: Aims: To compare the efficacy and safety of degludec U100 versus glargine U300 for the early postoperative management of patients with type 2 diabetes mellitus (T2D) undergoing coronary artery bypass graft (CABG) surgery. Methods: A total of 239 patients were randomly assigned (1:1) to receive a basal‐bolus regimen in the early postoperative period using degludec U100 ( n = 122) or glargine U300 ( n = 117) as basal and glulisine before meals. The primary outcome was mean differences between groups in their daily BG concentrations. The major safety outcome was the occurrence of hypoglycemia. Results: There were no differences in mean daily BG concentrations (157 vs. 162 mg/dl), mean percentage of readings within target BG of 70–180 mg/dl (74% vs. 73%), daily basal insulin dose (19 vs. 21 units/day), length of stay (median [IQR]: 9 vs. 9 days), or hospital complications (21.3% vs. 21.4%) between treatment groups. There were no differences in the proportion of patients with BG <70 mg/dl (15.6% vs. 23.1%) or <54 mg/dl (1.6% vs. 4.3%) between degludec‐100 and glargine‐300 groups. Conclusions: Treatment with degludec U100 is as effective and safe as glargine U300 for the early postoperative hospital management of patients with T2D undergoing CABG.